Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > EQRX EQRx > Detailed Quotes

EQRX EQRx

Watchlist
5.080
+0.500+10.92%
Close 10/04 16:00 ET
5.08000.00%
Post Mkt Price 10/04 16:02 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
5.115
Open
4.630
Turnover
22.35M
Low
4.610
Pre Close
4.580
Volume
4.53M
Market Cap
2.48B
P/E(TTM)
Loss
52wk High
9.990
Shares
488.14M
P/E(Static)
Loss
52wk Low
2.630
Float Cap
1.16B
Bid/Ask %
0.00%
Historical High
11.100
Shs Float
227.51M
Volume Ratio
1.52
Historical Low
2.630
Dividend TTM
--
Div Yield TTM
--
P/B
1.68
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.99%
Amplitude
11.03%
Avg Price
4.938
Lot Size
1
Float Cap
1.16B
Bid/Ask %
0.00%
Historical High
11.100
Shs Float
227.51M
Volume Ratio
1.52
Historical Low
2.630
Dividend TTM
--
P/B
1.68
Dividend LFY
--
Turnover Ratio
1.99%
Amplitude
11.03%
Avg Price
4.938
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company’s pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
CEO: --
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top